Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.

Roberts MJ, Yaxley JW, Coughlin GD, Gianduzzo TR, Esler RC, Dunglison NT, Chambers SK, Medcraft RJ, Chow CW, Schirra HJ, Richards RS, Kienzle N, Lu M, Brereton I, Samaratunga H, Perry-Keene J, Payton D, Oyama C, Doi SA, Lavin MF, Gardiner RA.

Contemp Clin Trials. 2016 Sep;50:16-20. doi: 10.1016/j.cct.2016.06.014. Epub 2016 Jun 28.

PMID:
27370230
2.

Quantitative assessment of the functional plasticity of memory CD8(+) T cells.

Baz A, Groves P, Buttigieg K, Apte SH, Kienzle N, Kelso A.

Eur J Immunol. 2016 Apr;46(4):863-73. doi: 10.1002/eji.201545726. Epub 2016 Feb 12.

3.

Polymer Coating of Carbon Nanotube Fibers for Electric Microcables.

Alvarez NT, Ochmann T, Kienzle N, Ruff B, Haase MR, Hopkins T, Pixley S, Mast D, Schulz MJ, Shanov V.

Nanomaterials (Basel). 2014 Nov 4;4(4):879-893. doi: 10.3390/nano4040879.

4.

Laparoscopic approach to a planned two-stage hepatectomy for bilobar colorectal liver metastases.

Kilburn DJ, Chiow AK, Lewin J, Kienzle N, Cavallucci DJ, Bryant R, O'Rourke N.

ANZ J Surg. 2016 Oct;86(10):811-815. doi: 10.1111/ans.12748. Epub 2014 Jul 2.

PMID:
24990234
5.

Circulating tumour cells--a bona fide cause of metastatic cancer.

Caixeiro NJ, Kienzle N, Lim SH, Spring KJ, Tognela A, Scott KF, de Souza P, Becker TM.

Cancer Metastasis Rev. 2014 Sep;33(2-3):747-56. doi: 10.1007/s10555-014-9502-8. Review.

PMID:
24817039
6.

Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer.

Lim SH, Becker TM, Chua W, Caixeiro NJ, Ng WL, Kienzle N, Tognela A, Lumba S, Rasko JE, de Souza P, Spring KJ.

Cancer Lett. 2014 Apr 28;346(1):24-33. doi: 10.1016/j.canlet.2013.12.019. Epub 2013 Dec 22. Review.

PMID:
24368189
7.

New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use.

Becker TM, Caixeiro NJ, Lim SH, Tognela A, Kienzle N, Scott KF, Spring KJ, de Souza P.

Int J Cancer. 2014 Jun 1;134(11):2523-33. doi: 10.1002/ijc.28516. Epub 2013 Oct 29. Review.

8.

Interleukin-4-induced loss of CD8 expression and cytolytic function in effector CD8 T cells persists long term in vivo.

Olver S, Apte SH, Baz A, Kelso A, Kienzle N.

Immunology. 2013 Jun;139(2):187-96. doi: 10.1111/imm.12068.

9.

IFN-gamma inhibits IL-4-induced type 2 cytokine expression by CD8 T cells in vivo and modulates the anti-tumor response.

Apte SH, Groves P, Olver S, Baz A, Doolan DL, Kelso A, Kienzle N.

J Immunol. 2010 Jul 15;185(2):998-1004. doi: 10.4049/jimmunol.0903372. Epub 2010 Jun 18.

10.

Interferon-gamma and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells.

Apte SH, Baz A, Groves P, Kelso A, Kienzle N.

Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17475-80. doi: 10.1073/pnas.0809549105. Epub 2008 Nov 6.

11.
12.

Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.

Olver S, Groves P, Buttigieg K, Morris ES, Janas ML, Kelso A, Kienzle N.

Cancer Res. 2006 Jan 1;66(1):571-80.

13.
14.

NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.

Morris ES, MacDonald KP, Rowe V, Banovic T, Kuns RD, Don AL, Bofinger HM, Burman AC, Olver SD, Kienzle N, Porcelli SA, Pellicci DG, Godfrey DI, Smyth MJ, Hill GR.

J Clin Invest. 2005 Nov;115(11):3093-103. Epub 2005 Oct 13.

15.

Memory cytolytic T-lymphocytes: induction, regulation and implications for vaccine design.

Baz A, Jackson DC, Kienzle N, Kelso A.

Expert Rev Vaccines. 2005 Oct;4(5):711-23. Review.

PMID:
16221072
16.

Progressive differentiation and commitment of CD8+ T cells to a poorly cytolytic CD8low phenotype in the presence of IL-4.

Kienzle N, Olver S, Buttigieg K, Groves P, Janas ML, Baz A, Kelso A.

J Immunol. 2005 Feb 15;174(4):2021-9.

17.

Profiling the CD8low phenotype, an alternative career choice for CD8 T cells during primary differentiation.

Kienzle N, Baz A, Kelso A.

Immunol Cell Biol. 2004 Feb;82(1):75-83. Review.

PMID:
14984598
18.

Murray Valley encephalitis: case report and review of neuroradiological features.

Kienzle N, Boyes L.

Australas Radiol. 2003 Mar;47(1):61-3. Review.

PMID:
12581057
19.

The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T cells at very low numbers.

Kienzle N, Olver S, Buttigieg K, Kelso A.

J Immunol Methods. 2002 Sep 15;267(2):99-108.

PMID:
12165431
20.

Antiserum raised against the Epstein-Barr virus BARF0 protein reacts to HLA-DR beta chain.

Schroder W, Kienzle N, Bushell G, Sculley T.

Arch Virol. 2002 Apr;147(4):723-9.

PMID:
12038683
21.
22.

Chryseobacterium in burn wounds.

Kienzle N, Muller M, Pegg S.

Burns. 2001 Mar;27(2):179-82.

PMID:
11226658
24.

Peptide-MHC class I tetrameric complexes display exquisite ligand specificity.

Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A.

J Immunol. 2000 Dec 1;165(11):6229-34.

25.

Differential splicing of antigen-encoding RNA reduces endogenous epitope presentation that regulates the expansion and cytotoxicity of T cells.

Kienzle N, Buck M, Silins SL, Burrows SR, Moss DJ, Winterhalter A, Brooks A, Khanna R.

J Immunol. 2000 Aug 15;165(4):1840-6.

26.

Aeromonas wound infection in burns.

Kienzle N, Muller M, Pegg S.

Burns. 2000 Aug;26(5):478-82.

PMID:
10812272
27.

Epstein-Barr virus-encoded RK-BARF0 protein expression.

Kienzle N, Buck M, Greco S, Krauer K, Sculley TB.

J Virol. 1999 Oct;73(10):8902-6.

28.

[Behavior therapy methods in treatment of schizophrenic adolescents].

Kienzle N, Althoff A.

Z Kinder Jugendpsychiatr Psychother. 1999 Aug;27(3):189-97. Review. German. No abstract available.

PMID:
10478438
30.

A-type and B-type Epstein-Barr virus differ in their ability to spontaneously enter the lytic cycle.

Buck M, Cross S, Krauer K, Kienzle N, Sculley TB.

J Gen Virol. 1999 Feb;80 ( Pt 2):441-5.

PMID:
10073706
31.

Intron retention may regulate expression of Epstein-Barr virus nuclear antigen 3 family genes.

Kienzle N, Young DB, Liaskou D, Buck M, Greco S, Sculley TB.

J Virol. 1999 Feb;73(2):1195-204.

32.

Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.

Kienzle N, Sculley TB, Poulsen L, Buck M, Cross S, Raab-Traub N, Khanna R.

J Virol. 1998 Aug;72(8):6614-20.

33.
34.

Association of human immunodeficiency virus Nef protein with actin is myristoylation dependent and influences its subcellular localization.

Fackler OT, Kienzle N, Kremmer E, Boese A, Schramm B, Klimkait T, Kücherer C, Mueller-Lantzsch N.

Eur J Biochem. 1997 Aug 1;247(3):843-51.

35.

Both A type and B type Epstein-Barr virus nuclear antigen 6 interact with RBP-2N.

Young DB, Krauer K, Kienzle N, Sculley T.

J Gen Virol. 1997 Jul;78 ( Pt 7):1671-4.

PMID:
9225044
36.

Evidence that the expression and phosphorylation status of pleckstrin is modulated by Epstein-Barr virus in human B lymphocytes.

Kienzle N, Cross S, Young DB, Misko I, Sculley TB, Abrams CS.

Blood. 1997 May 1;89(9):3488-90. No abstract available.

PMID:
9129059
37.

Epstein-Barr nuclear antigen-3 and -4 interact with RBP-2N, a major isoform of RBP-J kappa in B lymphocytes.

Krauer KG, Kienzle N, Young DB, Sculley TB.

Virology. 1996 Dec 15;226(2):346-53.

38.

Specific cleavage sites of Nef proteins from human immunodeficiency virus types 1 and 2 for the viral proteases.

Schorr J, Kellner R, Fackler O, Freund J, Konvalinka J, Kienzle N, Kräusslich HG, Mueller-Lantzsch N, Kalbitzer HR.

J Virol. 1996 Dec;70(12):9051-4.

39.

Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.

Kerr BM, Kienzle N, Burrows JM, Cross S, Silins SL, Buck M, Benson EM, Coupar B, Moss DJ, Sculley TB.

J Virol. 1996 Dec;70(12):8858-64.

40.

Induction of pleckstrin by the Epstein-Barr virus nuclear antigen 3 family.

Kienzle N, Young D, Silins SL, Sculley TB.

Virology. 1996 Oct 1;224(1):167-74.

41.

DNaseI treatment is a prerequisite for the amplification of cDNA from episomal-based genes.

Kienzle N, Young D, Zehntner S, Bushell G, Sculley TB.

Biotechniques. 1996 Apr;20(4):612-6. No abstract available.

42.

Subcloning of HIV-2 nef genes in E. coli and immunological reactivity of expressed fusion proteins.

Ulrich R, Siakkou H, Mayer J, Kienzle N, Müller-Lantzsch N, Krüger DH.

Virus Genes. 1993 Sep;7(3):229-40.

PMID:
8279123
43.

Oligomerization of the Nef protein from human immunodeficiency virus (HIV) type 1.

Kienzle N, Freund J, Kalbitzer HR, Mueller-Lantzsch N.

Eur J Biochem. 1993 Jun 1;214(2):451-7.

44.

Fine mapping of HIV-1 Nef-epitopes by monoclonal antibodies.

Siakkou H, Jahn S, Kienzle N, Ulrich R, Grötzinger C, Schneider T, Kohleisen B, Pauli G, Spohn R, Jung G, et al.

Arch Virol. 1993;128(1-2):81-95.

PMID:
7678193
45.

High frequency of antibodies against recombinant HIV-2 Nef protein in HIV-2-positive and HIV-negative sera.

Mayer J, Kienzle N, Ulrich R, Hunsmann G, Mueller-Lantzsch N.

AIDS. 1992 May;6(5):519-20. No abstract available.

PMID:
1616664
46.

Expression and cellular localization of the Nef protein from human immunodeficiency virus-1 in stably transfected B-cells.

Kienzle N, Bachmann M, Müller WE, Müller-Lantzsch N.

Arch Virol. 1992;124(1-2):123-32.

PMID:
1571013
47.

Expression of the HIV-1 Nef protein in the baculovirus system: investigation of anti-Nef antibodies response in human sera and subcellular localization of Nef.

Kienzle N, Enders M, Buck M, Siakkou H, Jahn S, Petzold G, Schneweis KE, Bachmann M, Müller WE, Müller-Lantzsch N.

Arch Virol. 1992;126(1-4):293-301.

PMID:
1524496
48.

Immunological study of the nef protein from HIV-1 by polyclonal and monoclonal antibodies.

Kienzle N, Bröker M, Harthus HP, Enders M, Erfle V, Buck M, Müller-Lantzsch N.

Arch Virol. 1991;118(1-2):29-41.

PMID:
2048974

Supplemental Content

Loading ...
Support Center